Tags

Type your tag names separated by a space and hit enter

In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection.

Abstract

The in vitro activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin MICs of 0.25 to 1 μg/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of ≤1 μg/ml may be too high. The remaining isolates had rifampin MICs of ≤0.016 μg/ml, and the rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm bactericidal concentrations (MBBC) for ≥50% of isolates were 8, 1, 2, and 4 μg/ml (for S. aureus) and 2, 0.06, 0.25, and 0.5 μg/ml (for S. epidermidis), respectively, for rifampin-susceptible isolates. Nonrifampin rifamycins have promising staphylococcal activity, including antibiofilm activity.

Authors+Show Affiliations

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA patel.robin@mayo.edu. Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31451499

Citation

Albano, Mariana, et al. "In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Planktonic and Biofilm States of Staphylococci Isolated From Periprosthetic Joint Infection." Antimicrobial Agents and Chemotherapy, vol. 63, no. 11, 2019.
Albano M, Karau MJ, Greenwood-Quaintance KE, et al. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection. Antimicrob Agents Chemother. 2019;63(11).
Albano, M., Karau, M. J., Greenwood-Quaintance, K. E., Osmon, D. R., Oravec, C. P., Berry, D. J., ... Patel, R. (2019). In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection. Antimicrobial Agents and Chemotherapy, 63(11), doi:10.1128/AAC.00959-19.
Albano M, et al. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Planktonic and Biofilm States of Staphylococci Isolated From Periprosthetic Joint Infection. Antimicrob Agents Chemother. 2019;63(11) PubMed PMID: 31451499.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection. AU - Albano,Mariana, AU - Karau,Melissa J, AU - Greenwood-Quaintance,Kerryl E, AU - Osmon,Douglas R, AU - Oravec,Caitlin P, AU - Berry,Daniel J, AU - Abdel,Matthew P, AU - Patel,Robin, Y1 - 2019/10/22/ PY - 2019/06/04/received PY - 2019/08/17/accepted PY - 2020/04/22/pmc-release PY - 2019/8/28/pubmed PY - 2019/8/28/medline PY - 2019/8/28/entrez KW - Staphylococcus aureus KW - Staphylococcus epidermidis KW - biofilm KW - periprosthetic joint infection KW - rifabutin KW - rifampin KW - rifamycins KW - rifapentine KW - rifaximin KW - rpoB JF - Antimicrobial agents and chemotherapy JO - Antimicrob. Agents Chemother. VL - 63 IS - 11 N2 - The in vitro activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin MICs of 0.25 to 1 μg/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of ≤1 μg/ml may be too high. The remaining isolates had rifampin MICs of ≤0.016 μg/ml, and the rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm bactericidal concentrations (MBBC) for ≥50% of isolates were 8, 1, 2, and 4 μg/ml (for S. aureus) and 2, 0.06, 0.25, and 0.5 μg/ml (for S. epidermidis), respectively, for rifampin-susceptible isolates. Nonrifampin rifamycins have promising staphylococcal activity, including antibiofilm activity. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/31451499/In_vitro_Activity_of_Rifampin,_Rifabutin,_Rifapentine_and_Rifaximin_Against_Planktonic_and_Biofilm_States_of_Staphylococci_Isolated_from_Periprosthetic_Joint_Infection L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=31451499 DB - PRIME DP - Unbound Medicine ER -